State Street Holds 5.2% Of Syndax — It Says The Stake Isn't For Control
The institution reported 4,653,172 shares, while Syndax's new finance chief received an option award tied to continued service.
State Street reported a 5.2% stake in Syndax Pharmaceuticals, which develops and sells cancer therapies, and certified that the holding was not intended to influence control. Its passive ownership disclosure filed Tuesday covered 4,653,172 common shares as of September 30.
Shared Votes, Passive Ownership
State Street reported shared voting authority over 4,436,323 shares and shared authority to dispose of all 4,653,172 shares. It reported no sole voting authority.
The institution certified that it obtained and held the securities as part of its ordinary business, rather than for a transaction aimed at changing or influencing Syndax's control.
Two Medicines On The Market
Syndax sells Revuforj, or revumenib, for certain relapsed or treatment-resistant acute leukemias involving a KMT2A translocation or an NPM1 mutation. Its other FDA-approved medicine, Niktimvo, or axatilimab-csfr, treats chronic graft-versus-host disease after at least two earlier systemic therapies.
Syndax leads sales of Revuforj and markets Niktimvo alongside Incyte. The partners split U.S. profits and losses equally. Syndax's own U.S. sales team serves hematologists, oncologists and transplant physicians; contract manufacturers supply its medicines, and it owns no manufacturing facilities.
Syndax had a market value of $860 million in Tuesday trading as of 9:53 a.m. ET.
Ondrey's Option Award
Syndax announced Aaron A. Ondrey's hiring as chief financial officer on Monday, November 2. He started the role Monday, November 9, and received an option to purchase up to 270,000 shares as an inducement to join.
The board set the exercise price at $9.55 per share, equal to Syndax's closing share price on Monday, November 9. The company said the option will vest over four years, provided Ondrey continues serving the company.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: SYNDAX PHARMACEUTICALS INC (SNDX) — SEC EDGAR
- Syndax Pharmaceuticals, Inc. (SNDX) Seasonal Returns Chart - Yahoo Finance — Yahoo Finance
- Syndax Pharmaceuticals Reports Inducement Grant Under — globenewswire.com